Long-term, open-label evaluation of the safety and efficacy of telmisartan 80 mg/hydrochlorothiazide 25 mg fixed-dose combination alone or with other antihypertensive medication

By Neldam Steen   Edwards Colin  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 3, 2009-02 ,pp. : 345-352

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed‐dose combination compared with individual components: A phase 1, open‐label, single‐dose study

By  

Clinical Pharmacology In Drug Development, Vol. 5, Iss. 2, 2016-03 ,pp. : 109-117

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bioequivalence of Sitagliptin/Metformin Fixed-Dose Combination Tablets and Concomitant Administration of Sitagliptin and Metformin in Healthy Adult Subjects: A Randomized, Open-Label, Crossover Study

By Migoya Elizabeth M.  

Clinical Drug Investigation, Vol. 30, Iss. 12, 2010-12 ,pp. : 855-866

Adis International

Access to resources Recommend Favorite

Tolerability and Safety of Topiramate in Chinese Patients with Epilepsy: An Open-Label, Long-Term, Prospective Study

By Lu Yang  

Clinical Drug Investigation, Vol. 27, Iss. 10, 2007-01 ,pp. : 683-690

Adis International

Access to resources Recommend Favorite

Long-Term Safety and Tolerability of the Oral Direct Renin Inhibitor Aliskiren with Optional Add-On Hydrochlorothiazide in Patients with Hypertension: A Randomized, Open-Label, Parallel-Group, Multicentre, Dose-Escalation Study with an Extension Phase

By Sica Domenic  

Clinical Drug Investigation, Vol. 31, Iss. 12, 2011-12 ,pp. : 825-837

Adis International

Access to resources Recommend Favorite